Sunday, March 20, 2022 10:36:37 PM
Of course. Overall Survival is the point of cancer treatments. Everything else including progression free survival is a short cut and not appropriate for a trial with a long fat tale of survivors. NWBO DcVax-L data should be extraordinary.
New SOC that is why there is so much FUD in opposition. Who's OX is eviscerated?
Good news is we can buy more stock at 10% of real intrinsic value. Right now!
At $3.50 - $5.00 it is a good buy that is where Institution will buy in putting a floor on the stock and where many retail will sell. Let you winners run! But at $0.75 it is an incredible buy.
NWBO is the 25x opportunity of 2022-2024.
Néed I remind everyone of Arrowhead and Anavex which 25x increased in 18 month's?
Relax the Linda's got this.
Not investment advice. But personally I think it is the best risk/reward in the market in years.
It will not take a lot of stock to make one comfortable. A large holding might make one a philanthropist. These are the aspirations of many NWBO investors.
Linda Powers got this. Stand by for windfall and let the company do the heavy lifting.
Up to you.
Northwest Bio. Shock & Awe.
50x in 24-36 months. No need for buy out but patience is critical.
New SOC that is why there is so much FUD in opposition. Who's OX is eviscerated?
Good news is we can buy more stock at 10% of real intrinsic value. Right now!
At $3.50 - $5.00 it is a good buy that is where Institution will buy in putting a floor on the stock and where many retail will sell. Let you winners run! But at $0.75 it is an incredible buy.
NWBO is the 25x opportunity of 2022-2024.
Néed I remind everyone of Arrowhead and Anavex which 25x increased in 18 month's?
Relax the Linda's got this.
Not investment advice. But personally I think it is the best risk/reward in the market in years.
It will not take a lot of stock to make one comfortable. A large holding might make one a philanthropist. These are the aspirations of many NWBO investors.
Linda Powers got this. Stand by for windfall and let the company do the heavy lifting.
Up to you.
Northwest Bio. Shock & Awe.
50x in 24-36 months. No need for buy out but patience is critical.
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
